Efficacy and safety analysis of different dose idarubicin plus cytarabine regimen as induction chemo

• 作 者: 张仪
• 机 构: 1st Affil Hosp,Zhejiang Univ,
• 出 处: China Medical Abstracts(Internal Medicine)
• 发表日期: 2016年04期
• 关键词: young myeloid chemotherapy regimen excluded prognosis induction enrolled favorab

Objective To compare the efficacy,safety and longterm prognosis between different dose idarubicin(IDA)combined with cytarabine(IA)as induction chemotherapy in newly diagnosed young patients of acute myeloid leukemia(AML).Methods A total of 149 newly diagnosed young AML patients(APL excluded)between January 2009 to July 2014 was enrolled.According to the

Objective To compare the efficacy, safety and longterm prognosis between different dose idarubicin (IDA) combined with cytarabine (IA) as induction chemotherapy in newly diagnosed young patients of acute myeloid leukemia (AML). Methods A total of 149 newly diagnosed young AML patients ( APL excluded) between January 2009 to July 2014 was enrolled. According to the